Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Genus Oncology LLC logo — Discovering New Frontiers in Anti-Cancer Therapeutics: Targe...

Genus Oncology LLC

Discovering New Frontiers in Anti-Cancer Therapeutics: Targeting MUC1 for a Healthier Tomorrow

Founded 2007 3 employees Series A Biotechnology, Health Care

General Information

Company Name Genus Oncology LLC
Founded Year 2007
Employees 3
Industries Biotechnology, Health Care
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Genus Oncology LLC. To contact Genus Oncology LLC, visit genusoncology.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Genus Oncology LLC compare?

A PDF of Genus Oncology LLC and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Genus Oncology LLC soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Genus Oncology LLC

Genus Oncology LLC, established in 2007, is dedicated to pioneering breakthroughs in anti-cancer therapeutics, focusing on targeting the Mucin 1 (MUC1) oncoprotein. Their mission, encapsulated in the slogan "Discovering New Frontiers in Anti-Cancer Therapeutics: Targeting MUC1 for a Healthier Tomorrow," addresses the crucial need for selective inhibition of MUC1, prevalent in various carcinomas and hematologic malignancies. Particularly significant is their Series A investment in 01 May 2011 from Lightbank, evidencing investor confidence in the potential of their innovative approach to combatting cancer.

The company's focused efforts in the biotechnology and health care sectors align with the burgeoning demand for advanced treatments in the field of oncology. By striving to tackle the pressing issue of tumor formation through selective targeting of MUC1, Genus Oncology shows promise in contributing to the development of effective anti-cancer agents. With this strategic focus, Genus Oncology positions itself as a compelling prospect for venture capital investors seeking to support groundbreaking advancements in cancer therapeutics.

Business keywords: anti-cancer therapeutics, MUC1 oncoprotein, cancer research, biopharmaceuticals, oncology, drug development, precision medicine, targeted therapy, tumor formation, biomedical research, cancer treatment, pharmaceutical industry

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A Undisclosed 1
Lightbank
Lightbank
01 May 2011

Genus Oncology LLC Alternatives & Competitors

View All Alternatives
Genus Oncology LLC vs
Soricimed Biopharma Inc.
Soricimed Biopharma Inc. Canada

Dedicated to developing effective and novel targeted treatments for cancer.

Grant
12 employees
Biopharma, Biotechnology
Genus Oncology LLC vs
AtG Therapeutics
AtG Therapeutics Spain

Overcoming Tumor Adaptation - inhibiting escape mechanisms both in treatment naive and resistant pat...

Seed
7 employees
Biotechnology, Health Care
Genus Oncology LLC vs
BoomRay Pharmaceuticals
BoomRay Pharmaceuticals China

成为国际一流、品质卓越的放射性药物公司 Global pioneer in radiopharmaceuticals and commitment to qual...

Series A
3 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Genus Oncology LLC

Discovering New Frontiers in Anti-Cancer Therapeutics: Targeting MUC1 for a Healthier Tomorrow
Genus Oncology LLC was founded in 2007.
Genus Oncology LLC operates in Biotechnology and Health Care. Its work centres on anti-cancer therapeutics, MUC1 oncoprotein, cancer research and biopharmaceuticals.
Genus Oncology LLC has approximately 3 employees.
Genus Oncology LLC has completed 1 funding round. The latest funding stage is Series A.
Top alternatives and competitors to Genus Oncology LLC include Soricimed Biopharma Inc., AtG Therapeutics, BoomRay Pharmaceuticals, PrecisemAb Biotech Co., Ltd., iOnctura. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Genus Oncology LLC and Soricimed Biopharma Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Genus Oncology LLC, https://bouncewatch.com/company/genus-oncology-llc, updated 25 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes